研究报告 Research Report 8 Sep 2025 安能物流（开曼） ANE (Cayman) (9956 HK) 2025H1 业绩点评：费控保障盈利韧性增长，中期分红超预期 FY2025H1 Performance Review: Expense Control Supports Profit Growth, Interim Dividend Exceeds Expectations [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$9.66 目标价 HK$11.60 HTI ESG 5.0-5.0-5.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$11.37bn / US$1.46bn 日交易额 (3 个月均值) US$3.10mn 发行股票数目 1,177mn 自由流通股 (%) 56% 1 年股价最高最低值 HK$9.66-HK$6.66 注：现价 ...

分化延续，终端需求需提振 [Table_Authors] 国内高频指标跟踪（2025 年第 36 期） 宏观研究 /[Table_Date] 2025.09.07 2025-09-08 告 本报告导读： 消费分化、投资平淡，生产短期有所调整，价格受需求因素主导 投资要点： 请务必阅读正文之后的免责条款部分 宏 观 研 究 宏 观 周 报 证 券 研 究 报 [Table_Report] [Table_Summary] 上周高频数据显示，消费方面，服务消费受暑期结束拖累，跨区域 迁徙、游乐场所客流等指标同比降幅扩大；商品消费分化，纺织服 装因秋冬备货需求回暖，汽车、高端白酒仍显弱势。投资方面，地 产市场仍处调整阶段，销售与土地市场平淡，尽管专项债发行进度 较快，但对基建实物工作量的支撑仍显不足。进出口方面，短期港 口数据走弱或反映出口表现一般，但美欧制造业 PMI 回升或预示下 阶段外需存在改善可能。生产方面，钢铁、轮胎等行业开工率下行， 反映短期政策影响和下游需求压力，而纯碱因玻璃、光伏需求支撑 表现较好。价格方面，CPI 平稳运行，PPI。流动性层面，跨月后资 金利率回落，央行逆回购净回笼调节流动性，美元指 ...

Investment Rating - Maintain OUTPERFORM rating with a target price of HK$67.35, current price at HK$32.76 [2][5] Core Insights - Revenue and profit showed steady growth in 25H1, driven by increased outpatient visits, with revenue reaching RMB 1.49 billion (+9.5%) and outpatient visits at 2.75 million (+15.3%) [3][11] - The company is focusing on the launch of AI avatars for doctors and overseas expansion, with expectations for significant commercial realization of AI products in 2025 [4][13] Financial Performance - Revenue breakdown for 25H1: offline revenue at RMB 1.37 billion (+11.1%) and online revenue at RMB 0.13 billion (-5.2%), indicating a stronger focus on offline medical institutions [3][11] - Gross margin improved to 30.6% (+1.2 pp), with net profit reaching RMB 150 million (+41.6%) and adjusted net profit at RMB 170 million (+15.2%) [4][12] - Forecasted revenue for 2025 and 2026 is RMB 3.40 billion and RMB 4.03 billion, respectively, with net profit projected at RMB 410 million and RMB 490 million [5][14] Operational Developments - The company added seven TCM clinics in 25H1, including three acquisitions and four self-built, and entered two new cities (Chengdu and Shantou) [3][11] - AI technology is being deployed to enhance service quality, with ten "National Physician AI Avatars" launched across various medical fields [4][13]

Investment Rating - The report maintains an "OUTPERFORM" rating for Hygeia Healthcare, with a target price of HK$35.17, indicating a significant upside from the current price of HK$14.58 [3][6]. Core Insights - The operating performance for the first half of 2025 remained relatively stable, with a notable improvement in cash flow [1][5]. - Revenue for 1H25 was RMB 1.99 billion, reflecting a year-over-year decline of 16.5% and a quarter-over-quarter decrease of 3.6%. Oncology services accounted for 44% of total revenue [4][13]. - The company operates 16 oncology-focused hospitals and is actively catering to international patients, particularly from Malaysia and Indonesia [4][13]. - Gross margin was under pressure due to new hospital openings and the impact of DRGs and centralized procurement, resulting in a gross margin of 26.6%, down 5.2 percentage points [4][14]. - Adjusted net profit for 1H25 was RMB 260 million, a decrease of 34.5% year-over-year but an increase of 30.2% quarter-over-quarter, with a net margin of 13.2% [4][14]. Financial Performance Summary - The company expects revenue for 2025 and 2026 to be RMB 4.49 billion and RMB 4.65 billion, respectively, with year-over-year growth of 1.0% and 3.7% [6][16]. - Adjusted net profit is projected to be RMB 610 million and RMB 690 million for 2025 and 2026, reflecting growth rates of 6.1% and 7.6% [6][16]. - Operating cash flow improved to RMB 460 million, a 29.9% increase, while capital expenditures decreased by 28.5% to RMB 240 million [5][15]. - Free cash flow surged to RMB 210 million, marking a significant increase of 1,611% [5][15]. Valuation and Market Position - Hygeia Healthcare is recognized as a leading private healthcare provider with quality hospital assets and long-term brand value, justifying the target price of HK$35.17, which corresponds to a P/E ratio of 32x for 2025 and 29x for 2026 [6][16]. - The company has a market capitalization of HK$9.02 billion (approximately US$1.16 billion) and a free float of 54% [3][6].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary sector, including Nike, Midea Group, JD Group, Haier Smart Home, Anta Sports, Gree Electric, and others [1]. Core Insights - The report emphasizes the focus on consumer sub-sectors with favorable risk/reward ratios, highlighting bottom opportunities in the market [1][4]. - The performance of various consumer sectors is analyzed, with gold and jewelry, overseas cosmetics, and domestic cosmetics showing positive growth, while luxury goods and overseas sportswear sectors experienced declines [4][12]. Sector Performance Review - Weekly performance rankings indicate that the gold and jewelry sector led with a 4.0% increase, followed by overseas cosmetics at 1.7% and domestic cosmetics at 1.4%. In contrast, overseas sportswear saw a significant decline of 4.2% [4][12]. - Monthly performance shows overseas cosmetics leading with an 8.8% increase, while overseas sportswear experienced a decline of 2.9% [12]. - Year-to-date performance highlights gold and jewelry with a remarkable 175.3% increase, while overseas sportswear faced a decline of 12.0% [12][13]. Sector Valuation Analysis - Most sectors are valued below their average over the past five years, with the overseas sportswear sector expected PE at 34.3 times, which is 61% of its historical average. The domestic sportswear sector is expected to have a PE of 14.1 times, 80% of its historical average [9][18]. - The gold and jewelry sector's expected PE is 27.1 times, 48% of its historical average, while the luxury goods sector is expected at 24.3 times, 44% of its historical average [9][18]. - The report indicates that all sectors' expected PE for 2025 is lower than their historical averages, with only the household goods sector's EV/EBITDA exceeding its historical average [18].

研究报告 Research Report 7 Sep 2025 中国可选消费 & 必需消费 China (Overseas) Discretionary & Staples 餐饮、潮玩及家电行业周报 F&B, Designer Toys and Home Appliance Sector Weekly Report [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | | --- | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | | 评级 | | 泡泡玛特 | Outperform 现代牧业 | | | Outperform | | 安踏体育 | Outperform 澳优 | | | Outperform | | 百威亚太 | Neutral | 九毛九 | | Outperform | | 华润啤酒 | Outperform | | | | | 华住酒店集团有限 | Outperform | | | | | 公司 | | | | | | 海底捞 | Outperform | | | | | 康 ...

The provided content does not contain any specific quantitative models or factors, nor does it include detailed construction processes, formulas, or backtesting results related to quantitative analysis. The document primarily discusses macroeconomic trends, sectoral outlooks, and investment strategies without delving into quantitative methodologies. If you have another document or specific section that includes quantitative models or factors, please provide it for analysis.

Investment Rating - The report suggests a positive investment outlook for the nuclear power sector, particularly focusing on small modular reactors (SMR) as a key energy solution for AI data centers and other high-energy demand technologies [5][34]. Core Insights - The North American core data center market has doubled in size since 2020, with vacancy rates dropping to approximately 2% and 70% of the 8GW under construction already pre-leased, indicating a supply gap that may persist until 2027 [17]. - The report highlights a significant increase in gas turbine price indices, with a year-on-year growth of 4.43% and a month-on-month increase of 3.8% as of July 2025, driven by tight supply-demand dynamics [19]. - The average spot price of uranium globally was reported at $75.13 per pound in July 2025, reflecting a 6% increase from the previous month, while heavy rare earth prices also showed upward trends [4]. Summary by Sections Global Infrastructure and Construction Equipment - The North American data center market has seen a substantial increase in size, with a vacancy rate of about 2% and a projected supply gap extending to 2027 [17]. - Companies are locking in capacity 18-24 months in advance, with rental rates increasing at a compound annual growth rate of 12% over three years [17]. Global Electrical and Intelligent Equipment - The gas turbine price index has shown significant growth, with a year-on-year increase of 4.43% and a month-on-month increase of 3.8% as of July 2025 [19]. - The report anticipates that the future growth of the gas turbine market in the U.S. will be driven primarily by the development of AI data centers [22]. Global Energy Industry - TVA is partnering with ENTRA1 to deploy six SMR power plants, aiming to add up to 6GW of new installed capacity, which could power approximately 4.5 million homes or 60 new data centers [32][33]. - The U.S. government is taking steps to accelerate the approval process for nuclear power deployment, with plans to significantly increase nuclear capacity by 2050 [35]. Global New Materials - The report notes that the average spot price of uranium was $75.13 per pound in July 2025, marking a 6% increase from the previous month [4]. Global Defense and Aerospace - The report indicates a stable recovery in the aerospace sector, with increased defense spending and modernization needs, suggesting potential investment opportunities in companies like BAE Systems and Howmet Aerospace [6].

Investment Rating - The report rates the company as "Outperform" with a target price of 128.60 RMB, representing a potential upside of 26% from the current price of 116.98 RMB [1][9]. Core Insights - The company is expected to achieve net profits attributable to shareholders of 1.93 billion RMB, 2.20 billion RMB, and 2.55 billion RMB for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 34.9%, 13.9%, and 16.0% [1][9]. - Earnings per share (EPS) for 2025 and 2026 are projected at 4.29 RMB and 4.88 RMB, respectively [1][9]. - The company achieved a revenue of 2.37 billion RMB in the first half of 2025, reflecting a year-on-year increase of 50.57%, and a net profit of 1.05 billion RMB, which is a 60.22% increase year-on-year [4][9]. Financial Summary - Total revenue is projected to grow from 2,018 million RMB in 2023 to 5,108 million RMB in 2025, representing a growth rate of 155.1% in 2023 and 43.6% in 2025 [2][6]. - Net profit attributable to shareholders is expected to rise from 644 million RMB in 2023 to 1,929 million RMB in 2025, with a growth rate of 393.5% in 2023 and 34.9% in 2025 [2][6]. - The company’s net asset return rate (ROE) is projected to be 27.6% in 2025, down from 16.2% in 2023 [2][6]. Clinical Development and Market Potential - The company’s drug, Furmonertinib, is expanding its indications domestically and is showing positive results in overseas trials, particularly for 1L PACC mutation NSCLC [4][9]. - The second Phase III clinical trial for Furmonertinib is set to commence, with the first patient enrollment expected in the second half of 2025 [4][9]. - The approval of Golireser for 2L KRAS G12C mutation NSCLC patients in May 2025 indicates the company’s successful progression in clinical trials [4][9].

Investment Rating - The report maintains an "Outperform" rating for Jiayou International, with a target price of 14.43 RMB, representing a potential upside of 16% from the current price [5][8]. Core Insights - Jiayou International's performance in the first half of 2025 faced pressure, with a revenue decline of 11.99% year-on-year to 4.08 billion RMB and a net profit attributable to shareholders down 26.15% to 561 million RMB [9][10]. - The China-Mongolia business is expected to recover in the second half of 2025 due to rebounding coal prices and increased demand for Mongolian coal, with forecasts indicating a net profit of 1.32 billion RMB for 2025 [5][11]. - The company's African operations are showing strong growth, with a 34% increase in revenue from land port projects and a 40% increase in gross profit in the first half of 2025, contributing to future profit growth [11][10]. Financial Summary - Total revenue is projected to be 8.67 billion RMB in 2025, with a slight decrease of 0.9% from the previous year, followed by a significant increase to 11.08 billion RMB in 2026 [4]. - Net profit attributable to shareholders is expected to be 1.32 billion RMB in 2025, with a gradual increase to 1.96 billion RMB by 2027 [5][4]. - Earnings per share (EPS) are forecasted to be 0.96 RMB in 2025, increasing to 1.43 RMB by 2027 [5][4].